18 fired at Novartis for fabricating sales data of diabetes drug Galvus

The Swiss drug manufacturer Novartis has dismissed 18 sales executives for fabricating and inflating sales numbers of its diabetes drug Galvus. The  sales executives reportedly used sales incentives provided by the company to buy stocks from wholesalers and show an increase in sales of the drug in order to meet their target quota. PharmaAsia News  reported that Galvus executives are being investigated for allegedly padding invoices and then buying stocks of the drug from wholesalers with cash rewards given them as incentives. Jeffrey Newman represents whistleblowers.